The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective

Andre Lamy, John Eikelboom, Wesley Tong, Fei Yuan, Shrikant I. Bangdiwala, Jackie Bosch, Stuart Connolly, Eva Lonn, Gilles R. Dagenais, Kelley R. H. Branch, Wei-Jhih Wang, Deepak L. Bhatt, Jeffrey Probstfield, Georg Ertl, Stefan Störk, P. Gabriel Steg, Victor Aboyans, Isabelle Durand-Zaleski, Lars Ryden, Salim Yusuf, Unknown

Open source

DOI: 10.1007/s40256-023-00620-6
Published: 2023-12-28
Container: American Journal of Cardiovascular Drugs
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40256-023-00620-6,
  title = {The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective},
  author = {Andre Lamy and John Eikelboom and Wesley Tong and Fei Yuan and Shrikant I. Bangdiwala and Jackie Bosch and Stuart Connolly and Eva Lonn and Gilles R. Dagenais and Kelley R. H. Branch and Wei-Jhih Wang and Deepak L. Bhatt and Jeffrey Probstfield and Georg Ertl and Stefan Störk and P. Gabriel Steg and Victor Aboyans and Isabelle Durand-Zaleski and Lars Ryden and Salim Yusuf and Unknown},
  year = {2023},
  journal = {American Journal of Cardiovascular Drugs},
  doi = {10.1007/s40256-023-00620-6},
  url = {https://doi.org/10.1007/s40256-023-00620-6}
}

RIS

TY  - JOUR
TI  - The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
AU  - Andre Lamy
AU  - John Eikelboom
AU  - Wesley Tong
AU  - Fei Yuan
AU  - Shrikant I. Bangdiwala
AU  - Jackie Bosch
AU  - Stuart Connolly
AU  - Eva Lonn
AU  - Gilles R. Dagenais
AU  - Kelley R. H. Branch
AU  - Wei-Jhih Wang
AU  - Deepak L. Bhatt
AU  - Jeffrey Probstfield
AU  - Georg Ertl
AU  - Stefan Störk
AU  - P. Gabriel Steg
AU  - Victor Aboyans
AU  - Isabelle Durand-Zaleski
AU  - Lars Ryden
AU  - Salim Yusuf
AU  - Unknown
PY  - 2023
JO  - American Journal of Cardiovascular Drugs
DO  - 10.1007/s40256-023-00620-6
UR  - https://doi.org/10.1007/s40256-023-00620-6
ER  -

APA

Lamy, A., Eikelboom, J., Tong, W., Yuan, F., Bangdiwala, S. I., Bosch, J., Connolly, S., Lonn, E., Dagenais, G. R., Branch, K. R. H., Wang, W., Bhatt, D. L., Probstfield, J., Ertl, G., Störk, S., Steg, P. G., Aboyans, V., Durand-Zaleski, I., Ryden, L., Yusuf, S., & Unknown (2023). The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-023-00620-6

Source records

crossref · retrieved 2026-11-08T21:08:52.449Z